Clinical Trials Registration Information

Recorded Webinars - Sessions I, II, III, IV, V, and VI Registration & Reporting Guidelines and Best Practices 
In these sessions, Tony Keys, Johns Hopkins University, explains the regulatory requirements related to clinical and answers any questions you may have about common issues responsible parties encounter when using the system.

10-31-2019: Update to the PRS website

This change enables the record to differentiate between studies affiliated with the University of Maryland, Baltimore and the University of Maryland, College Park.


For general questions please contact:

Jan Martinez
IRB Manager
Phone: 410-706-5037
Martina Miller
IRB Analyst
Phone: 410-706-3869

* To Obtain a PRS account needed to create a entry, please contact Martina Miller and provide your name, phone number, and email address

NIH Implemented Reforms

Over the last few years, the National Institutes of Health has begun implementing a series of clinical trials reforms designed to enhance the accountability and transparency of clinical research. These reforms affect grants and contracts involving clinical trials, and several changes took effect on January 25, 2018.

Below are several key NIH reforms of importance to the NHLBI research community: 

  • Clinical trial-specific funding opportunities: Applications and proposals involving clinical trials with due dates on or after January 25, 2018, must be submitted to a funding opportunity announcement (FOA) or request for proposal (RFP) that explicitly states it will accept clinical trials. After January 25, 2018, the NIH will only accept clinical trial applications when submitted to parent announcements or other FOAs that specify clinical trials.
  • New Human Subjects and Clinical Trial Information form: The NIH will require the use of a new application form that consolidates all information related to human subjects and clinical trials into one place, and also expands the information required for studies that meet the NIH definition of a clinical trial. This form will be included in the newFORMS-E Application Packages to be used for all due dates after January 25, 2018. 
  • Single IRB policy for multi-site research: For applications with due dates after January 25, 2018, and contract solicitations published after January 25, 2018, the NIH expects that all sites participating in multi-site studies that involve non-exempt human subjects research funded by the NIH will use a single Institutional Review Board (sIRB) to conduct the ethical review required for the protection of human subjects.  This requirement applies to all applicable human subjects studies, not just trials.
  • Registering and reporting for NIH-funded clinical trials: All NIH-funded clinical trials are expected to register and submit results information to to help ensure that information about clinical trials and their results are made publicly available, in a timely manner.
  • Clinical Trials Protocol Template for Phase II and III Clinical Trials Conducted Under an IND or IDE: Investigators are encouraged to use a template and electronic protocol-writing tool, developed by the NIH and the Food and Drug Administration, to help evaluate the scientific basis of their assumptions, minimize uncertainty in the interpretation of outcomes, and prevent loss of data.
  • Good Clinical Practice Training: The NIH expects all NIH-funded clinical investigators and trial staff who are involved in the design, conduct, oversight, or management of clinical trials to be trained in Good Clinical Practice to help ensure the safety, integrity, and quality of clinical trials.

Resources for more information:

Any questions? Please email: